Indivior Projects Strong 2026 Profitability with 35% Adjusted EBITDA Growth and Resolves DOJ Matter
INDV has more than doubled off its 52-week low of $7.62.
Summary
Indivior PLC announced strong full-year 2026 financial guidance, projecting significant Adjusted EBITDA growth and substantial operating expense savings, alongside an 11% increase in SUBLOCADE net revenue. The company also confirmed the full payment of its $295 million legacy U.S. Department of Justice obligation.
Key Events · Earnings and Guidance · INDV
-
Strong 2026 Financial Guidance
Indivior projects full-year 2026 Adjusted EBITDA to grow by 35% to a midpoint of $555 million, with a 14 percentage point margin expansion to 48%.
-
SUBLOCADE Revenue Growth
Net revenue for SUBLOCADE is expected to increase by 11% to a midpoint of $925 million in 2026, driven by accelerated dispense unit growth.
-
Significant Operating Expense Savings
The company anticipates at least $150 million in annual non-GAAP operating expense savings in 2026, contributing to margin expansion.
-
Resolution of DOJ Obligation
Indivior has fully paid the outstanding $295 million obligation related to a legacy U.S. Department of Justice matter, eliminating a major legal and financial risk.
Analysis · INDV · Life Sciences
Indivior PLC's 2026 financial guidance signals a robust outlook, driven by an expected 35% increase in Adjusted EBITDA and substantial operating expense reductions of at least $150 million. This profitability expansion is supported by an 11% projected growth in net revenue for SUBLOCADE, the company's key opioid use disorder treatment. The successful resolution of the $295 million legacy U.S. Department of Justice matter removes a significant financial and legal overhang, further de-risking the investment profile. These developments, coupled with the company's strategic "Accelerate" phase and inclusion in the S&P SmallCap 600 index, position Indivior for enhanced financial performance and increased investor confidence.
At the time of this filing, INDV was trading at $35.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.5B. The 52-week trading range was $7.62 to $38.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.